Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts on ESMO 2024 Annual Meeting

BARCELONA, Spain, Sept. 20, 2024 /PRNewswire/ -- The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place from September 13 to 17 in Barcelona, Spain. As one of the most influential annual gatherings in oncology, this congress brings together leading cancer experts and researchers from around the globe, showcasing the latest advancements in the field and providing high-quality educational and networking opportunities for oncology professionals.

Biosyngen, an innovative biotechnology company specializing in immune cell therapies, has showcased its groundbreaking technology on gene-modified, functionally enhanced tumor-infiltrating lymphocytes (TILs) derived from liver cancer biopsy samples.

BioSyngen has secured ten clinical trial approvals in China and the U.S. for its innovative fourth-generation oncology therapies. Currently, our leading pipeline product, BRG01, is in the pivotal Phase II clinical trial stage for solid tumors. Additionally, the first patients have been enrolled in the Phase I trials for our other groundbreaking therapies, BST02 and BRL03, with completion of Phase I trials anticipated later this year.

Abstract Title

Pre-clinical Development of Genetically Modified Tumor-infiltrating Lymphocytes using Biopsy Samples from Liver Cancer Patients

Abstract No.

1034P

Tumor-infiltrating lymphocytes (TILs) are heterogeneous lymphocyte populations within the tumor microenvironment that contains T cells capable of recognizing tumor- or virus-associated antigens. In February of this year, the FDA approved the first TIL-based therapy used with IL-2 for advanced metastatic/recurrent melanoma. However, due to the variability in T cell infiltration between hot and cold tumors, differential abundance of antigen-specific T cells with robust immune response functionality, and the dependence of TIL anti-tumor efficacy on concomitant use of high-dose IL-2 combination therapy, the therapeutic applications of non-edited TILs are quite limited outside of melanoma.

To address these challenges, Biosyngen has developed a proprietary platform for expanding TILs from biopsy samples, achieving production of 10¹¹ cells within four weeks. Additionally, the company has established a stable gene modification platform that reprograms TIL metabolism, enhances TIL activity and sustained antitumor efficacy by expressing membrane anchor proteins. Anti-tumor efficacy has significantly enhanced (without IL-2 co-injection) and no obvious toxicity observed.

Biosyngen houses best-in-class proprietary TIL platform aiming to expand the clinical applications of TIL technology with following features:

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts on ESMO 2024 Annual Meeting

Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts on ESMO 2024 Annual Meeting

ZURICH, Dec. 30, 2024 /PRNewswire/ -- Amcor (NYSE: AMCR, ASX: AMC), a global leader in developing and producing responsible packaging solutions, announced today it completed the sale of its 50% interest in Bericap North America (BCNA) for $122 million on December 27, with the proceeds used to reduce debt.

Fiscal 2024 total sales for the joint venture were approximately $190 million and adjusted EBIT was approximately $19 million, both of which were previously fully consolidated under Amcor's Rigid Packaging business. Adjusted net income attributable to Amcor for fiscal 2024 was approximately $8 million. Net of the resulting reduction in interest expense, the transaction is not expected to have an impact on Amcor's financial outlook for fiscal 2025.  

About Amcor

Amcor is a global leader in developing and producing responsible packaging solutions across a variety of materials for food, beverage, pharmaceutical, medical, home and personal-care, and other products. Amcor works with leading companies around the world to protect products, differentiate brands, and improve supply chains. The Company offers a range of innovative, differentiating flexible and rigid packaging, specialty cartons, closures and services. The company is focused on making packaging that is increasingly recyclable, reusable, lighter weight and made using an increasing amount of recycled content. In fiscal year 2024, 41,000 Amcor people generated $13.6 billion in annual sales from operations that span 212 locations in 40 countries. NYSE: AMCR; ASX: AMC 
www.amcor.com I LinkedIn I YouTube

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Amcor completes previously announced sale of BCNA joint venture interest for $122 million; Proceeds used to reduce debt